Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
Source: https://www.zacks.com/commentary/2878485/3-generic-drug-stoc…
Analysts favor many sector names for rapid sales growth and big gains for the stocks over the next year.
Inflation has negatively impacted consumer staples companies. Conagra stock has lost 50% of its value over the last three years.
AI spending isn’t slowing down, as enterprises and governments are trying to take advantage of this technology’s productivity gains. Palantir Technologies and Intel are benefiting from different AI niches and are poised for healthy long-term growth.
